Literature DB >> 10460828

Naturally occurring anti-alpha-galactosyl antibodies: relationship to xenoreactive anti-alpha-galactosyl antibodies.

W Parker1, S S Lin, P B Yu, A Sood, Y C Nakamura, A Song, M L Everett, J L Platt.   

Abstract

Antibodies produced by an individual without a known history of sensitization to the relevant antigen are called "natural" antibodies. Some natural antibodies, called xenoreactive antibodies, react with the cells of foreign species. Most xenoreactive antibodies in humans and higher primates bind to a nonreducing terminal galactose expressed by pigs and other lower mammals. Although human natural antibodies which bind to one or more of a variety of terminal alpha-galactosyl structures have been identified previously, the antigen recognized by anti-alpha-galactosyl antibodies on the cells of foreign species is thought to be exclusively Galalpha1-3Gal. Thus, anti-alpha-galactosyl antibodies which do not react with Galalpha1-3Gal are thought to be nonxenoreactive. Here, we identify natural antibodies in human serum which bind to Galalpha1-6Hexosepyrranosides but not Galalpha1-3Gal, indicating that these antibodies are not xenoreactive. Various lower mammals were found to have natural anti-Galalpha1-2Gal antibodies in their sera, suggesting that at least some anti-Galalpha1-2Gal antibodies might not be xenoreactive and indicating, surprisingly, that anti-alpha-galactosyl antibodies are much more phylogenetically disperse than previously known. Also surprising was the finding that some natural antibodies which bind to Galalpha1-3Gal in vitro do not bind to porcine xenografts. These studies show that naturally occurring anti-alpha-galactosyl antibodies in mammalian serum include antibodies with a greater variety of reactivities than previously thought, only some of which would bind to a porcine xenograft. Further, these studies show that the methods used to detect anti-alpha-galactosyl antibodies of relevance in xenotransplantation must be carefully evaluated to avoid detection of anti-alpha-galactosyl antibodies which would not bind to a porcine organ and which therefore are not involved in xenograft rejection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460828     DOI: 10.1093/glycob/9.9.865

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  12 in total

1.  Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors:  J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

Review 2.  α-Gal Nanoparticles in Wound and Burn Healing Acceleration.

Authors:  Uri Galili
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

Review 3.  Immune-directed support of rich microbial communities in the gut has ancient roots.

Authors:  Larry J Dishaw; John P Cannon; Gary W Litman; William Parker
Journal:  Dev Comp Immunol       Date:  2014-06-28       Impact factor: 3.636

4.  Presence of natural anti-Galalpha1-4GalNAcbeta1-3Gal (anti-NOR) antibodies in animal sera.

Authors:  Maria Duk; Elwira Lisowska
Journal:  Glycoconj J       Date:  2006-11       Impact factor: 2.916

5.  Natural IgG antibody with anti-β-galactosyl specificity suppressed hepatoma cell invasion in culture.

Authors:  Yutaka Miura; Hiroshi Fujita; Fumihiko Sakai; Hiroyuki Tachikawa; Kazumi Yagasaki; Daisaburo Fujimoto
Journal:  Cytotechnology       Date:  2012-12-19       Impact factor: 2.058

6.  Induced Remodeling of Porcine Tendons to Human Anterior Cruciate Ligaments by α-GAL Epitope Removal and Partial Cross-Linking.

Authors:  Kevin R Stone; Ann Walgenbach; Uri Galili
Journal:  Tissue Eng Part B Rev       Date:  2017-02-14       Impact factor: 6.389

7.  The Formation of Glycan-Specific Natural Antibodies Repertoire in GalT-KO Mice Is Determined by Gut Microbiota.

Authors:  Daniel Bello-Gil; Christophe Audebert; Sara Olivera-Ardid; Magdiel Pérez-Cruz; Gaël Even; Nailya Khasbiullina; Nausicaa Gantois; Nadezhda Shilova; Sophie Merlin; Cristina Costa; Nicolai Bovin; Rafael Mañez
Journal:  Front Immunol       Date:  2019-03-05       Impact factor: 7.561

8.  Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection.

Authors:  Anne Lamontagne; Ronald E Long; Mary Ann Comunale; Julie Hafner; Lucy Rodemich-Betesh; Mengjun Wang; Jorge Marrero; Adrian M Di Bisceglie; Timothy Block; Anand Mehta
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

9.  Gut microbiota elicits a protective immune response against malaria transmission.

Authors:  Bahtiyar Yilmaz; Silvia Portugal; Tuan M Tran; Raffaella Gozzelino; Susana Ramos; Joana Gomes; Ana Regalado; Peter J Cowan; Anthony J F d'Apice; Anita S Chong; Ogobara K Doumbo; Boubacar Traore; Peter D Crompton; Henrique Silveira; Miguel P Soares
Journal:  Cell       Date:  2014-12-04       Impact factor: 41.582

Review 10.  Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.

Authors:  Uri Galili
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.